Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.
Fiscal year to December 2025, from the company's annual filing with the SEC.
| Salesyearly sales | $12.2B |
| Sales growthchange from the year before | +10.3% |
| Gross marginshare of sales left after the direct cost of what it sells | 83.0% |
| Operating marginshare of sales left after running the business | 20.8% |
| Net marginshare of sales kept as profit | 20.5% |
| Return on invested capitalprofit made on each $100 put into the business | 19.7% |
| Return on equityprofit vs. shareholders' accounting value | 30.6% |
| Debt / equitydebt vs. shareholders' accounting value | 0.24 |
| Change in share countnegative = the company is buying back its shares | -3.4% |
3 insiders sold $320.5M (all under pre-arranged plans) on the open market.
| Blecharczyk NathanChief Strategy Officer · Director · 10% owner | Sold (plan)Aug 3 | 13,615 shat $151.80 · $2.1M |
| Mertz ElinorChief Financial Officer | Sold (plan)Aug 3 | 3,748 shat $153.34 · $575K |
| Gebbia JosephDirector · 10% owner | Sold (plan)Jul 28 | 1,828,303 shat $151.67 · $277.3M |
From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.
Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy